Provided by Tiger Trade Technology Pte. Ltd.

CorMedix Inc.

7.19
-0.2300-3.10%
Post-market: 7.260.0700+0.97%19:30 EDT
Volume:1.13M
Turnover:8.17M
Market Cap:560.42M
PE:3.45
High:7.45
Open:7.45
Low:7.17
Close:7.42
52wk High:13.02
52wk Low:6.13
Shares:77.94M
Float Shares:66.02M
Volume Ratio:1.44
T/O Rate:1.70%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.08
EPS(LYR):2.04
ROE:54.93%
ROA:24.56%
PB:1.22
PE(LYR):3.52

Loading ...

CorMedix Price Target Announced at $15.00/Share by Oppenheimer

Dow Jones
·
Sep 23

Oppenheimer Initiates CorMedix at Outperform With $15 Price Target

MT Newswires Live
·
Sep 23

US Research Roundup- Allstate, Autozone, Vertex Pharmaceuticals

Reuters
·
Sep 23

CorMedix's New Major DefenCath Customer Backs 2026 Volumes, Durability Through 2027, RBC Says

MT Newswires Live
·
Aug 14

Annovis Bio Q2 Loss Widens as R&D Costs Rise

Reuters
·
Aug 14

RBC Adjusts Price Target on CorMedix to $14 From $13, Maintains Outperform Speculative Risk Rating

MT Newswires Live
·
Aug 14

CorMedix Shares Rise After Q2 Results, Guidance

MT Newswires Live
·
Aug 14

Analysts Are Bullish on Top Healthcare Stocks: Parabilis Medicines, Inc. (PBLS), Cormedix (CRMD)

TIPRANKS
·
Aug 14

U.S. Stocks on the MOVE-EnerSys, Netflix, Salesforce

Reuters
·
Aug 14

CorMedix Stock Jumps on Strong DefenCath Sales

Benzinga Earnings
·
Aug 13

CorMedix Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 13

CorMedix Shares Rise 7.1% Premarket After Q2 Revenue Beat

THOMSON REUTERS
·
Aug 13

CorMedix Beats Q2 Revenue Estimates on DefenCath Growth, Raises FY Adjusted Ebitda Guidance

Reuters
·
Aug 13

Cormedix Q2 EPS $0.29 Beats $0.25 Estimate, Sales $101.931M Beat $95.621M Estimate

Benzinga Earnings
·
Aug 13

CorMedix Q2 2026 Net Income Rises 31.1% to $26 Million; Revenue More than Doubled to $101.9 Million

Reuters
·
Aug 13

CorMedix Q2 Cash & Investments USD 256.7 Million

THOMSON REUTERS
·
Aug 13

CorMedix - Maintains FY 2026 Revenue Guidance $325-$345 Mln; Raises FY Adj Ebitda Guidance to $125-$140 Mln

THOMSON REUTERS
·
Aug 13

CorMedix Q2 Basic EPS USD 0.33

THOMSON REUTERS
·
Aug 13

CorMedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

THOMSON REUTERS
·
Aug 13

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Aug 13